01 / DESIGN
What was studied?
The phase 3 GLORY-2 study randomized Chinese adults with obesity to mazdutide or placebo alongside shared lifestyle support.
02 / FINDINGS
What did the researchers report?
The study reported greater sixty-week weight reduction with mazdutide. Gastrointestinal adverse reactions were more frequent in the active-treatment group.
03 / LIMITS
How should it be interpreted?
This population and regimen differ from other mazdutide trials. A weight endpoint does not establish every long-term health outcome, and adverse effects remain part of the interpretation.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.